Curcumin extract for prevention of type 2 diabetes

Diabetes Care

Volumn 35, Issue 11, 2012, Pages 2121-2127

  Chuengsamarn, Somlak ^a,b   Rattanamongkolgul, Suthee ^a   Luechapudiporn, Rataya ^c   Phisalaphong, Chada ^d   Jirawatnotai, Siwanon ^e,f  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Thailand Government Pharmaceutical Organization   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; CURCUMIN; INSULIN; PLACEBO; PROINSULIN;

ADULT; ARTICLE; CELL FUNCTION; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

CURCUMIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PREDIABETIC STATE; TREATMENT OUTCOME;

EID: 84868150021     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0116     Document Type: Article

References (32)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053 (Pubitemid 38579764)
2. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-932
3. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403 (Pubitemid 34437694)
4. Rydén L, Standl E, Bartnik M, et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136
5. Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC; Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators. Effect of Rosiglitazone and Ramipril on beta-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 2010;33:608-613
6. Kochhar KP. Dietary spices in health and diseases (II). Indian J Physiol Pharmacol 2008;52:327-354
7. Aggarwal BB. Targeting inflammation-induced obesity andmetabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010;30:173-199
8. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated infl ammation and diabetes in mouse models of diabesity. Endocrinology 2008;149:3549-3558 (Pubitemid 351919581)
9. Shao W, Yu Z, Chiang Y, et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE 2012;7:e28784
10. Kuroda M, Mimaki Y, Nishiyama T, et al. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 2005;28:937-939 (Pubitemid 40740674)
11. Nishiyama T, Mae T, Kishida H, et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005;53:959-963 (Pubitemid 40270383)
12. Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNFalpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 2009;11:241-249
13. Jacob A, Wu R, Zhou M, Wang P. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation. PPAR Res 2007;2007:89369
14. Kanitkar M, Gokhale K, Galande S, Bhonde RR. Novel role of curcumin in the prevention of cytokine-induced islet death in vitro and diabetogenesis in vivo. Br J Pharmacol 2008;155:702-713
15. Seo KI, Choi MS, Jung UJ, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008;52:995-1004
16. Jang EM, Choi MS, Jung UJ, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 2008;57:1576-1583
17. American Diabetes Association. Executive summary: Standards of medical care in diabetes d2012. Diabetes Care 2012;35(Suppl. 1):S4-S10
18. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197
19. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-1334
20. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). JAlternComplementMed 2003;9:161-168 (Pubitemid 36297021)
21. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndromeda new worldwide definition. Lancet 2005;366:1059-1062 (Pubitemid 41338752)
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
23. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K. Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab 2003;285:E155-E162 (Pubitemid 36736372)
24. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410 (Pubitemid 32269192)
25. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
26. DupontWD, PlummerWD Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998;19:589-601 (Pubitemid 29057724)
27. Yokoyama H, Emoto M, Mori K, et al. Plasma adiponectin level is associated with insulin-stimulated nonoxidative glucose disposal. J Clin Endocrinol Metab 2006;91:290-294 (Pubitemid 43069151)
28. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and metaanalysis. JAMA 2009;302:179-188
29. Aekplakorn W, Bunnag P, Woodward M, et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care 2006;29:1872-1877 (Pubitemid 44156645)
30. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol 2007;595:471-480
31. Collins M, McFarlane JR. An exploratory study into the effectiveness of a combination of traditional Chinese herbs in the management of type 2 diabetes. Diabetes Care 2006;29:945-946 (Pubitemid 44115326)
32. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003;26:1277-1294 (Pubitemid 36929285)